secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2021-08-10T23:59:59+00:00
Accession:  0001558370-21-011129
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune Q2 net loss $24.8M; ALT-801 Phase 1 data expected Sept 2021
---------------------------------------------------------------------

- Q2 net loss $24.8M ($0.60/shr) vs $16.8M ($0.94/shr) prior year; revenue $0.1M down from $0.7M.
- Cash, equivalents & investments $217.9M; raised $18.2M net via ATM in Q2.
- Recorded $8.1M impairment on construction-in-progress for terminated COVID-19 vaccine program.
- ALT-801 Phase 1 12-week data readout on three dose cohorts expected September 2021.
- IND for NASH on track for Q3 2021; obesity IND planned Q4 2021; Phase 2 trials targeted early 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000155837021011129/0001558370-21-011129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000155837021011129/alt-20210810x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-011129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer